CD40 ligand (CD40L) deficiency is an uncommon primary immune deficiency disorder caused by X-linked mutations in the CD40L gene and resulting in hyper-IgM syndrome, clinically characterized by sinopulmonary and gastrointestinal opportunistic infections, whereas neurologic symptoms are rare.1 Herein, we present a case of CD40L deficiency in childhood associated with the development of a generalized chorea, successfully treated with deep brain stimulation (DBS) of the globus pallidus interna (GPi).
Clinical case
Our patient presented with recurrent fever in the context of low immunoglobulin G (IgG) and immunoglobulin A (IgA). He was diagnosed with hyper-IgM syndrome at seven months of age secondary to a 1.5kb sub-genic deletion encompassing exon 3 of the CD40L gene. By age 3, he began receiving regular IV immune globulin. At the age of 13 years, he developed rapidly progressive visual deterioration due to optic atrophy, a new onset choreoathetoid movement disorder, cognitive deterioration, and generalized epilepsy. The deterioration occurred over a 2-year period. Hyperkinetic movements were bilateral, with choreoathetosis predominantly afflicting the head, neck, and limbs, which resolved during sleep.
MRI findings included supratentorial volume loss, subtle fluid-attenuation inversion recovery hyperintensity involving the insular regions, posterior periventricular and deep white matter, and mild symmetric T2 hypointensity bilaterally involving the globus pallidus (figure, A and B). Serial MRIs demonstrated progressive supratentorial volume loss over 2 years. The CSF analysis was unremarkable.
(A and B) show axial and coronal T2 preoperative images demonstrating supratentorial volume loss and bilateral T2 globus pallidus hypointensity. (C) Coronal T2 sequence illustrating deep brain stimulation electrodes. (D) Immunohistological image demonstrating CD3 positivity (brown) indicative of lymphocytosis.
The patient was treated empirically for a suspected neuroinflammatory process with steroids, plasma exchange and rituximab as well as symptomatically for hyperkinetic movements with tetrabenazine and clonidine. Chorea remained severe and intractable such that he became bound to bed (video 1, segment 1) and required bilateral GPi DBS (figure, C). A simultaneous cortical biopsy revealed lymphocytosis (T cells) of the leptomeninges and parenchyma with activated microglia (figure, D). Microbiological analysis of the specimen was negative.
Video 1
Demonstrating our patient's choreiform movements preoperatively and after the initiation of stimulation 5 days postoperatively.Download Supplementary Video 1 via http://dx.doi.org/10.1212/000899_Video_1
DBS was programmed on the fifth postoperative day with 2V and double monopolar settings bilaterally. An immediate decrease of choreiform movements was observed (video 1, segment 2). The patient's Movement Disorder Childhood Rating Scale from 4 to 18 years score improved from 22/28 preoperatively to 15/28 postoperatively.
After an excellent initial response, within 6 weeks, the patient experienced a recurrence of choreiform movements predominantly affecting the head and neck, prompting sequential adjustments of the DBS settings (table e-1, links.lww.com/NXI/A331). The patient continues to experience substantial symptomatic relief 6 months after surgery.
Discussion
More than 200 variants of the CD40L gene have been identified, including a subset of mutations which encompass exon 3, as in our case.1,2 All variants result in phenotypes of CD40L deficiency, which is the most common form of hyper-IgM syndrome.1 CD40L mediates interactions between T cells and other cells via contact with its receptor, CD40. Deficiency of the CD40/CD40L axis deleteriously affects biologic pathways of different cell lineages which manifests as defective cellular and humoral immunity. Patients are particularly vulnerable to opportunistic infections.3
The evolution of symptoms and supratentorial volume loss we observed on sequential imaging is consistent with progressive neurodegeneration. Iron accumulation within the globi pallidi may explain the hypointense MRI appearance, though we believe this to be a secondary, rather than primary phenomenon. Although CNS infections are known to occur in cases of CD40L deficiency (incidence >10%), neurodegeneration is rare. Nevertheless, it is a recognized, though poorly understood phenomenon and thought to occur in the setting of primary immunodeficiency disorders secondary to chronic meningoencephalitis and/or an autoimmune process.4,5 Autoimmune complications manifest in 20% of patients with CD40L deficiency due to an improper maintenance of tolerance.5 A favorable initial response to steroids, together with the brain biopsy results support the possibility of an inflammatory process in this case, however the underlying pathogenesis is unclear.
Movement disorders can rarely occur as sequelae to disorders of immunity such as AIDS.6 A choreiform movement disorder evolving in the context of CD40L deficiency reported herein, is an unusual association. Although the GPi has proved to be a successful stimulation target in other hyperkinetic disorders of childhood, the effect in this case was uncertain prior to implantation.7 DBS, rather than lesioning effect, is the most likely cause of improvement as the immediate and significant reduction of choreiform movements occurred following commencement of stimulation on the fifth postoperative day and has continued during 6 months of follow-up.
We have described a rare intractable movement disorder of childhood related to primary immunodeficiency, which was resistant to medical therapy. GPi DBS has returned some quality of life. We advocate early consideration of the treatment in medically resistant hyperkinetic movement disorders.
Study funding
No targeted funding reported.
Disclosure
The authors did not receive any funding/sponsorship in relation to the above clinical case report. The authors do not have any relevant funding disclosures to make. Go to Neurology.org/NN for full disclosures.
Acknowledgment
The authors are grateful for the assistance provided by Cynthia Hawkins and Famida Spatare from the Division of Neuropathology at the Hospital for Sick Children, Toronto, for preparing the histological image.
Appendix Authors
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.
Written consent was obtained from the patient's legal guardian including permission to include images and a video as part of the study.
- Received May 27, 2020.
- Accepted in final form August 31, 2020.
- Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.